BioPharma Dive June 18, 2025
Actio Biosciences’ Series B round will be used to support research initially focused on rare diseases, but it sees having broad potential, too.
Dive Brief:
- Actio Biosciences, a San Diego-based biotechnology startup, announced Wednesday it raised a $66 million Series B financing to support drug research it’s initially aiming at rare genetic diseases, but sees having broader potential, too.
- Actio’s most advanced program is in early-stage testing for the degenerative nerve disorder Charcot-Marie-Tooth disease, but may also be useful in treating overactive bladder, the company said. A second program focused on a genetic form of epilepsy is expected to enter the clinic by the end of the year.
- The startup’s Series B round was co-led by new investor Regeneron...
Today's Sponsors
Today's Sponsor